A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® for the Treatment of Chronic Sialorrhea in Pediatric Subjects
Latest Information Update: 27 Sep 2024
Price :
$35 *
At a glance
- Drugs Botulinum toxin B (Primary)
- Indications Sialorrhoea
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 11 Sep 2024 Planned End Date changed from 30 Mar 2024 to 1 May 2023.
- 11 Sep 2024 Planned primary completion date changed from 31 Dec 2023 to 1 May 2023.
- 11 Sep 2024 Planned initiation date changed from 30 Nov 2023 to 1 Nov 2021.